Role of Metabolic Enzymes in Non-Melanoma Skin Cancer
2 other identifiers
observational
26
1 country
2
Brief Summary
The researcher can proved that certain compounds play an important role in the prevention of skin cancer. Researcher can use specific compounds, which classified as metabolic enzymes, and lower concentrations and complete absent in skin cancer cells. Researcher can biopsies of normal skin and precancerous or cancerous lesions, and can compare the concentrations of these compounds to determine the difference between the two areas. The result can lead to further understanding of skin cancers and pre-cancers. Because skin cancers and pre-cancers are so common, any knowledge would be very useful for many people in the future and may be used for development of future treatments or prevention strategies.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Mar 2011
Longer than P75 for all trials
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 1, 2011
CompletedFirst Submitted
Initial submission to the registry
September 10, 2014
CompletedFirst Posted
Study publicly available on registry
September 19, 2014
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2015
CompletedStudy Completion
Last participant's last visit for all outcomes
August 1, 2015
CompletedNovember 1, 2022
October 1, 2022
4.4 years
September 10, 2014
October 28, 2022
Conditions
Outcome Measures
Primary Outcomes (1)
expression levels of metabolic enzymes in normal skin versus precancerous lesions or skin cancer
Overall, compare normal skin versus precancerous lesions or skin cancer from the same individual. Paired tests of samples are selected from the same subjects. * 10 actinic keratosis samples, * 10 basal cell carcinoma samples * 20 squamous cell carcinoma samples * Normal skin control biopsy from the same subject will be collected.
1 month
Study Arms (1)
skin specimen
skin specimen
Interventions
Eligibility Criteria
Study population will be selected from University of California Irvine Medical Cencal
You may qualify if:
- Male or Female are age18 years and older
- Have normal skin and a skin lesion of interest
- Willing to have skin biopsies on those areas
You may not qualify if:
- Male or Female are under 18 years of age
- Pregnant women
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
Beckman Laser Institute
Irvine, California, 92612, United States
Gottschalk Medical Plaza, 1 Medical Plaza Drive
Irvine, California, 92697, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Kristen Kelly, MD
Beckman Laser Institute, UCI
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Kirsten Kelly, M.D., Professor of Dermatology and Surgery
Study Record Dates
First Submitted
September 10, 2014
First Posted
September 19, 2014
Study Start
March 1, 2011
Primary Completion
August 1, 2015
Study Completion
August 1, 2015
Last Updated
November 1, 2022
Record last verified: 2022-10